{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T22:00:21Z","timestamp":1770069621367,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"name":"Fio Cruz"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-017-0192-z","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T07:08:55Z","timestamp":1515049735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Pharmacokinetics comparison of two pegylated interferon alfa formulations in healthy volunteers"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-2545","authenticated-orcid":false,"given":"Marisa Boff","family":"Costa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Dornelles","family":"Picon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guilherme Becker","family":"Sander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo Nodarse","family":"Cuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmen Valenzuela","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando P\u00e1ez","family":"Meireles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Carolina Magalh\u00e3es Andrade","family":"G\u00f3es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia Maria","family":"Batoreu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria de Lourdes de Sousa","family":"Maia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Maciel","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise Cristina de Souza","family":"Matos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Lopez","family":"Saura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,1,4]]},"reference":[{"key":"192_CR1","doi-asserted-by":"crossref","unstructured":"Qi Y, Chilkoti A. Protein-polymer conjugation-moving beyond PEGylation. Curr Opin Chem Biol. 2015 Oct; 28:181-193. PubMed PMID: 26356631. eng.","DOI":"10.1016\/j.cbpa.2015.08.009"},{"key":"192_CR2","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang H, Ma Z, Wu B. Effects of pharmaceutical PEGylation on drug metabolism and its clinical concerns. Expert Opin Drug Metab Toxicol. 2014 Dec; 10(12): 1691-1702. PubMed PMID: 25270687. eng.","DOI":"10.1517\/17425255.2014.967679"},{"key":"192_CR3","doi-asserted-by":"crossref","unstructured":"Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC. et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001 Aug; 34(2): 395-403. PubMed PMID: 11481625. eng.","DOI":"10.1053\/jhep.2001.26371"},{"key":"192_CR4","doi-asserted-by":"crossref","unstructured":"Reddy KR, Wright TL, Pockros PJ, Shiffman M, Everson G, Reindollar R. et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001 Feb; 33(2):433-438. PubMed PMID: 11172346. eng.","DOI":"10.1053\/jhep.2001.21747"},{"key":"192_CR5","doi-asserted-by":"crossref","unstructured":"Castanheira LG, Barbano DB, Rech N. Current development in regulation of similar biotherapeutic products in Brazil. Biologicals. 2011 Sep; 39(5): 308-311. PubMed PMID: 21868247. eng.","DOI":"10.1016\/j.biologicals.2011.06.021"},{"key":"192_CR6","doi-asserted-by":"crossref","unstructured":"Ramon J, Saez V, Baez R, Aldana R, Hardy E. PEGylated interferon-alpha2b: a branched 40K polyethylene glycol derivative. Pharm res. 2005 Aug; 22(8): 1374-1386. PubMed PMID: 16078148. eng.","DOI":"10.1007\/s11095-005-5278-4"},{"issue":"3","key":"192_CR7","first-page":"3521","volume":"32","author":"R P\u00e1ez-Meireles","year":"2015","unstructured":"P\u00e1ez-Meireles R, Castro-Odio FR, Hern\u00e1ndez JR, Torres D, Cosme C, Nodarse H, et al. Increased bioavailability of IFN a 2b modificed by chemical conjugation to a two-branched polyethyleneglycol molecule. Biotecnol Apl, jul-sep. 2015;32(3):3521\u20133. ISSN 1027-2852","journal-title":"Biotecnol Apl, jul-sep"},{"key":"192_CR8","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Garc\u00eda I, Gonz\u00e1lez-Delgado CA, Valenzuela-Silva CM, D\u00edaz-Machado A, Cruz-D\u00edaz M, Nodarse-Cun\u00ed H, et al. Pharmacokinetic and pharmacodynamic comparison of two \u201cpegylated\u201d interferon alpha-2 formulations in healthy male volunteers: a randomized, crossover, double-blind study. BMC Pharmacol. 2010;10:15. PubMed PMID: 21092287. eng.","DOI":"10.1186\/1471-2210-10-15"},{"key":"192_CR9","doi-asserted-by":"crossref","unstructured":"Fan J, de Lannoy IA. Pharmacokinetics. Biochem Pharmacol. 2014 Jan 1; 87(1):93-120. PubMed PMID: 24055064. eng.","DOI":"10.1016\/j.bcp.2013.09.007"},{"key":"192_CR10","volume-title":"Pharmacokinetic and pharmacodynamic data analysis: concepts and applications","author":"J Gabrielsson","year":"2006","unstructured":"Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis: concepts and applications. 4th ed. Stockholm: Swedish Pharmaceutical Press; 2006.","edition":"4"},{"key":"192_CR11","doi-asserted-by":"crossref","unstructured":"Asahina Y, Izumi N, Umeda N, Hosokawa T, Ueda K, Doi F, Tsuchiya K. et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin. J Viral Hepat. 2007 Jun; 14(6): 396-403. PubMed PMID: 17501760. eng.","DOI":"10.1111\/j.1365-2893.2006.00803.x"},{"key":"192_CR12","doi-asserted-by":"crossref","unstructured":"Reddy KR. Development and pharmacokinetics and pharmacodynamics of pegylated interferon alfa-2a (40 kD). Semin Liver Dis. 2004; 24 Suppl 2:33-38. PubMed PMID: 15346244. eng.","DOI":"10.1055\/s-2004-832926"},{"key":"192_CR13","doi-asserted-by":"crossref","unstructured":"Bruno R, Sacchi P, Cima S, Maiocchi L, Novati S, Filice G, et al. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. J Viral Hepat. 2012 Jan; 19 Suppl 1:33-36. PubMed PMID: 22233411 eng.","DOI":"10.1111\/j.1365-2893.2011.01519.x"},{"key":"192_CR14","doi-asserted-by":"crossref","unstructured":"Foster G. Pegylated Interferons for the treatment of chronic hepatitis C. Pharmacological and clinical differences between Peginterferon-a-2a and Peginterferon-a-2b. Drugs. 2010; 70(2):147-165. PubMed PMID: 20108989. eng.","DOI":"10.2165\/11531990-000000000-00000"},{"key":"192_CR15","doi-asserted-by":"crossref","unstructured":"Richter WF, Jacobsen B. Subcutaneous absorption of biotherapeutics: knowns and unknowns. Drug Metab Dispos. 2014 Nov; 42(11): 1881-1889. PubMed PMID: 25100673. eng.","DOI":"10.1124\/dmd.114.059238"},{"key":"192_CR16","doi-asserted-by":"crossref","unstructured":"Vinogradova SV, Zhudenkov KV, Benson N, Van Der Graaf PH, Demin OV, Karelina TA. Prediction of long-term treatment outcome in HCV following 24 day PEG-IFN alpha-2b therapy using population pharmacokinetic-pharmacodynamic mixture modeling and classification analysis. J Theor Biol. 2015 Oct 7; 382:91-98. PubMed PMID: 26163367. eng.","DOI":"10.1016\/j.jtbi.2015.06.041"},{"key":"192_CR17","doi-asserted-by":"crossref","unstructured":"Khakoo S, Glue P, Grellier L, Wells B, Bell A, Dash C. et al. Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions. Br J Clin Pharmacol. 1998 Dec; 46(6): 563-570. PubMed PMID: 9862245. eng.","DOI":"10.1046\/j.1365-2125.1998.00836.x"},{"key":"192_CR18","doi-asserted-by":"crossref","unstructured":"Scavone C, Sportiello L, Rafaniello C, Mascolo A, Sessa M, Rossi F. et al. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opin Drug Saf. 2016 Dec; 15(sup2): 85-100. PubMed PMID: 27875916. eng.","DOI":"10.1080\/14740338.2016.1221396"},{"key":"192_CR19","unstructured":"Pan American Health Organization, Data from: Reporting on Strategic Information on Viral Hepatitis B and C Survey 2015\u201316, Washington DC, PAHO, 2016."},{"key":"192_CR20","doi-asserted-by":"crossref","unstructured":"Langhans B, Nischalke HD, Kr\u00e4mer B, Hausen A, Dold L, van Heteren P. et al. Increased peripheral CD4<sup>+<\/sup> regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C. J Hepatol. 2016 Dec 29. [Epub ahead of print]. PubMed PMID: 28040549. eng.","DOI":"10.1016\/j.jhep.2016.12.019"},{"key":"192_CR21","doi-asserted-by":"crossref","unstructured":"Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D. et al. Adjuvant treatment with pegylated interferon \u03b1-2a versus low-dose interferon \u03b1-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial. Ann Oncol. 2016 Aug; 27(8): 1625-1632. PubMed PMID: 27287206. eng.","DOI":"10.1093\/annonc\/mdw225"},{"key":"192_CR22","doi-asserted-by":"crossref","unstructured":"Koskenvesa P, Kreutzman A, Rohon P, Pihlman M, Vakkila E, R\u00e4s\u00e4nen A. et al. Imatinib and pegylated IFN-\u03b12b discontinuation in first-line chronic myeloid leukemia patients following a major molecular response. Eur J Haematol. 2014; 92(5): 413-420. PubMed PMID: 24372965. eng.","DOI":"10.1111\/ejh.12258"},{"key":"192_CR23","doi-asserted-by":"crossref","unstructured":"Moriya F, Ogasawara S, Basaki Y, Akiba J, Kojiro S, Fukahori S. et al. Growth inhibitory effects of pegylated IFN-alpha2b and 5-fluorouracil in combination on renal cell carcinoma cell lines in vitro and in vivo. Int J Oncol. 2008 Oct; 33(4): 647-655. PubMed PMID: 18813777. eng.","DOI":"10.3892\/ijo_00000050"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-017-0192-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T21:03:27Z","timestamp":1570568607000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-017-0192-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["192"],"URL":"https:\/\/doi.org\/10.1186\/s40360-017-0192-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,4]]},"article-number":"1"}}